What data are being used to support the approval of Strattera?
In six placebo-controlled registration studies, two in children, two in children and adolescents, and two in adults, Strattera significantly reduced core symptoms of ADHD, and was well tolerated. In all studies, participants met Diagnostic and Statistical Manual, 4th Edition (DSM-IV-TR) , criteria for ADHD. Eli Lilly and Company is continuing to study Strattera in short-term and long-term trials. As of April 2005, more than 6,000 child and adolescents have taken Strattera in clinical trials for ADHD.
Related Questions
- How much data has been used to support the clearance of the Menaflex device compared to that provided in submissions for other cleared surgical meshes?
- If monitoring data were used to support the initial tolerance decision, do valid current monitoring data exist?
- How can the NAPLAN Data Service be used to support teaching and learning programs in schools?
